FDA Warning To Skin-Care Firm Shows Perils Of Cosmetics-To-Drug Transition

FDA's warning letter to skin-care product firm MW Laboratories for marketing unapproved new drugs illustrates the potentially perilous transition from marketing cosmeceuticals to making OTC claims